Erytech Pharma Sa Stock Current Valuation
| ERYPDelisted Stock | USD 0.78 0.04 4.88% |
Valuation analysis of Erytech Pharma SA helps investors to measure Erytech Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Erytech Pharma's price fluctuation is very steady at this time. Calculation of the real value of Erytech Pharma SA is based on 3 months time horizon. Increasing Erytech Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Erytech Pharma's intrinsic value may or may not be the same as its current market price of 0.78, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.78 | Real 0.74 | Hype 0.78 |
The intrinsic value of Erytech Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Erytech Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Erytech Pharma SA helps investors to forecast how Erytech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Erytech Pharma more accurately as focusing exclusively on Erytech Pharma's fundamentals will not take into account other important factors: Erytech Pharma SA Company Current Valuation Analysis
Erytech Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Erytech Pharma Current Valuation | 211.16 K |
Most of Erytech Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Erytech Pharma SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Erytech Pharma SA has a Current Valuation of 211.16 K. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Erytech Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Erytech Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Erytech Pharma could also be used in its relative valuation, which is a method of valuing Erytech Pharma by comparing valuation metrics of similar companies.Erytech Pharma is currently under evaluation in current valuation category among its peers.
Erytech Fundamentals
| Return On Equity | -0.0098 | |||
| Return On Asset | -0.3 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (4.08) % | |||
| Current Valuation | 211.16 K | |||
| Shares Outstanding | 34.12 M | |||
| Shares Owned By Institutions | 7.65 % | |||
| Number Of Shares Shorted | 17.79 K | |||
| Price To Earning | (5.88) X | |||
| Price To Book | 0.65 X | |||
| Price To Sales | 7.58 X | |||
| Gross Profit | 4.18 M | |||
| EBITDA | (22.69 M) | |||
| Net Income | (228 K) | |||
| Cash And Equivalents | 54.05 M | |||
| Cash Per Share | 1.74 X | |||
| Total Debt | 13.57 M | |||
| Debt To Equity | 1.00 % | |||
| Current Ratio | 2.25 X | |||
| Book Value Per Share | 0.76 X | |||
| Cash Flow From Operations | (31.76 M) | |||
| Short Ratio | 0.10 X | |||
| Earnings Per Share | (0.01) X | |||
| Target Price | 2.96 | |||
| Number Of Employees | 49 | |||
| Beta | 2.13 | |||
| Market Capitalization | 29.57 M | |||
| Total Asset | 45.81 M | |||
| Retained Earnings | (228 K) | |||
| Working Capital | 30.96 M | |||
| Current Asset | 94.53 M | |||
| Current Liabilities | 9.8 M | |||
| Z Score | 0.48 | |||
| Net Asset | 45.81 M |
About Erytech Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Erytech Pharma SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Erytech Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Erytech Pharma SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Erytech Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Erytech Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Erytech Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Erytech Stock
| 0.33 | WMT | Walmart Aggressive Push | PairCorr |
The ability to find closely correlated positions to Erytech Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Erytech Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Erytech Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Erytech Pharma SA to buy it.
The correlation of Erytech Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Erytech Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Erytech Pharma SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Erytech Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Erytech Stock
If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |